title: Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention.
abstract: Despite the recent progress in interferon (IFN) therapies for chronic hepatitis C, liver cirrhosis remains refractory. One of the major obstacles to successful IFN therapy is low platelet count. Currently, splenic interventions, such as partial splenic embolization (PSE) or surgical splenectomy, have been applied effectively and make standard IFN therapy possible. However, there may be a group of patients with low platelet counts who can be treated without splenic intervention. We here report two patients with advanced type C liver cirrhosis who were successfully treated using very-low-dose pegylated interferon a2a plus ribavirin. One patient had a very low platelet count (2.5 x 10(4)/mul) due to splenomegaly before treatment. However, pretreatment serum HCV titers were low in both patients and early viral responses were obtained in both. Because PSE or splenectomy may still have some safety concerns, this attenuated IFN treatment protocol can be an alternative therapeutic option for patients with advanced type C liver disease, but good virological factors for sustained virological response.
authors.affiliation: Division of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
authors.forename: Shogo
authors.initials: S
authors.lastname: Ohkoshi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamagiwa
authors.forename: Masahiko
authors.initials: M
authors.lastname: Yano
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Takahashi
authors.forename: Yo-Hei
authors.initials: YH
authors.lastname: Aoki
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Matsuda
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Aoyagi
references.citation: J Viral Hepat. 2006 Nov;13(11):762-9
references.pmid: 17052276
references.citation: J Gastroenterol. 2009;44(10):1009-15
references.pmid: 19756352
references.citation: Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S141-3
references.pmid: 16234063
references.citation: Hepatol Res. 2008 Dec;38(12):1159-71
references.pmid: 18684129
references.citation: Nat Clin Pract Gastroenterol Hepatol. 2008 Nov;5(11):610-22
references.pmid: 18838975
references.citation: World J Gastroenterol. 2008 Oct 28;14(40):6140-4
references.pmid: 18985803
references.citation: J Gastroenterol. 2006 Jan;41(1):17-27
references.pmid: 16501853
references.citation: Clin Ther. 2004 Jul;26(7):991-1025
references.pmid: 15336466
references.citation: Hepatol Res. 2008 Mar;38(3):225-33
references.pmid: 18034810
references.citation: Eur J Gastroenterol Hepatol. 2005 Feb;17(2):179-84
references.pmid: 15674095
references.citation: J Hepatol. 2007 Oct;47(4):484-91
references.pmid: 17692985
references.citation: Ann Intern Med. 2003 Feb 18;138(4):299-306
references.pmid: 12585827
references.citation: Dig Dis Sci. 2002 Feb;47(2):388-91
references.pmid: 11855556
references.citation: NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46
references.pmid: 14768714
references.citation: Hepatology. 2006 Dec;44(6):1543-54
references.pmid: 17133492
references.citation: Hepatol Res. 2008 Oct;38(10):980-6
references.pmid: 18657124
references.citation: Scand J Gastroenterol. 2008;43(11):1378-86
references.pmid: 18615358
references.citation: Hepatology. 2006 Dec;44(6):1675-84
references.pmid: 17133499
references.citation: Eur J Gastroenterol Hepatol. 2005 Nov;17(11):1157-64
references.pmid: 16215426
references.citation: J Viral Hepat. 2007 Nov;14 Suppl 1:82-8
references.pmid: 17958648
references.citation: Hepatology. 2003 Sep;38(3):645-52
references.pmid: 12939591
references.citation: Antivir Ther. 2004 Dec;9(6):1027-30
references.pmid: 15651761